NYSEAMERICAN:IMUC - ImmunoCellular Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$0.20 -0.01 (-4.76 %)
(As of 09/23/2018 04:00 PM ET)
Previous Close$0.20
Today's Range$0.20 - $0.2150
52-Week Range$0.03 - $0.55
Volume268,049 shs
Average Volume737,407 shs
Market Capitalization$8.07 million
P/E RatioN/A
Dividend YieldN/A
Beta0.67
ImmunoCellular Therapeutics logoImmunoCellular Therapeutics, Ltd., a clinical-stage biotechnology company, develops immune-based therapies for the treatment of various cancers. Its products include ICT-107, a dendritic cell (DC) immunotherapy for the treatment of diagnosed glioblastoma multiforme (GBM); ICT-140, a DC-based immunotherapy targets tumor associated antigens on ovarian cancer; and ICT-121, a DC-based immunotherapy targeting CD133 markers and CSCs to treat recurrent GBM and other solid tumor cancers. The company is developing Steam-to-T-Cell immunotherapies for the treatment of cancer. It has license agreements with California Institute of Technology and The Johns Hopkins University. The company was formerly known as Optical Molecular Imaging, Inc. and changed its name to ImmunoCellular Therapeutics, Ltd. in November 2006. ImmunoCellular Therapeutics, Ltd. is based in Westlake Village, California.

Receive IMUC News and Ratings via Email

Sign-up to receive the latest news and ratings for IMUC and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Biotechnology
Sub-IndustryBiotechnology
SectorMedical
SymbolNYSEAMERICAN:IMUC
CUSIP45253610
Phone+1-818-2642300

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on Assets-270.08%

Miscellaneous

EmployeesN/A
Outstanding Shares41,940,000
Market Cap$8.07 million

ImmunoCellular Therapeutics (NYSEAMERICAN:IMUC) Frequently Asked Questions

What is ImmunoCellular Therapeutics' stock symbol?

ImmunoCellular Therapeutics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "IMUC."

How were ImmunoCellular Therapeutics' earnings last quarter?

ImmunoCellular Therapeutics Ltd (NYSEAMERICAN:IMUC) announced its earnings results on Monday, August, 13th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter. View ImmunoCellular Therapeutics' Earnings History.

When is ImmunoCellular Therapeutics' next earnings date?

ImmunoCellular Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, November, 20th 2018. View Earnings Estimates for ImmunoCellular Therapeutics.

Are investors shorting ImmunoCellular Therapeutics?

ImmunoCellular Therapeutics saw a drop in short interest in the month of August. As of August 31st, there was short interest totalling 1,944,696 shares, a drop of 10.5% from the August 15th total of 2,172,247 shares. Based on an average daily trading volume, of 192,878 shares, the short-interest ratio is presently 10.1 days. Approximately 4.7% of the company's shares are sold short. View ImmunoCellular Therapeutics' Current Options Chain.

Who are some of ImmunoCellular Therapeutics' key competitors?

Who are ImmunoCellular Therapeutics' key executives?

ImmunoCellular Therapeutics' management team includes the folowing people:
  • Mr. Gary S. Titus, Chairman & Corp. Sec. (Age 58)
  • Dr. Anthony J. Gringeri, CEO, Pres & Director (Age 65)
  • Dr. John S. Yu, Founder & Director (Age 54)
  • Mr. David E. Fractor, Chief Financial Officer (Age 58)
  • Dr. Steven J. Swanson, Sr. VP of Research (Age 62)

How do I buy shares of ImmunoCellular Therapeutics?

Shares of IMUC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ImmunoCellular Therapeutics' stock price today?

One share of IMUC stock can currently be purchased for approximately $0.20.

How big of a company is ImmunoCellular Therapeutics?

ImmunoCellular Therapeutics has a market capitalization of $8.07 million.

What is ImmunoCellular Therapeutics' official website?

The official website for ImmunoCellular Therapeutics is http://imuc.com/.

How can I contact ImmunoCellular Therapeutics?

ImmunoCellular Therapeutics' mailing address is 30721 Russell Ranch Rd Ste 140, WESTLAKE VILLAGE, CA 91362-7383, United States. The biotechnology company can be reached via phone at +1-818-2642300.


MarketBeat Community Rating for ImmunoCellular Therapeutics (NYSEAMERICAN IMUC)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  197 (Vote Outperform)
Underperform Votes:  187 (Vote Underperform)
Total Votes:  384
MarketBeat's community ratings are surveys of what our community members think about ImmunoCellular Therapeutics and other stocks. Vote "Outperform" if you believe IMUC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IMUC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel